Is it time to stage prostate cancer using molecular imaging?
Prostate cancer is one of the most common cancers in men. After the diagnosis is made, staging should be undertaken with imaging methods in order to plan the treatment and predict the prognosis. Parallel to technological developments in recent years, new imaging methods have entered into cl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ali İhsan Taşçı
2022-06-01
|
| Series: | Yeni Üroloji Dergisi |
| Online Access: | https://dergipark.org.tr/en/pub/yud/issue/70180/1035767 |
| Summary: | Prostate cancer is one of the most common cancers in men. After the diagnosis is made, staging should be undertaken with imaging methods in order to plan the treatment and predict the prognosis. Parallel to technological developments in recent years, new imaging methods have entered into clinical use. Among these methods, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has come to the fore since it provides anatomical and functional imaging and has many advantages in tumor (T), nodal (N) and metastatic (M) staging. This review discusses the current status of the PSMA- PET method in prostate cancer staging. Keywords: prostate cancer, staging, positron emission tomography |
|---|---|
| ISSN: | 1305-2489 2687-1955 |